Recent Updates — TOIIW

On August 20, 2026, Starling Oncology Management, LLC entered into a $25 million revolving credit facility with Gemino Healthcare Finance, LLC. As of the closing date on August 21, 2026, $4.75 million was outstanding. The facility matures on August 20, 2029, bears interest at Term SOFR plus 3.95%, and is secured by accounts receivable. Starling Oncology operates in the healthcare industry, providing oncology services.

Starling Oncology reported second quarter 2026 financial results, posting consolidated revenue of $161.3 million, a 34.6% increase from the prior year period. Gross profit rose 55.2% to $27.2 million, while net loss narrowed to $9.8 million compared to $17.0 million previously. Adjusted EBITDA turned positive at $229 thousand, up from a $4.1 million loss. The company raised its full-year 2026 revenue guidance to $650–$670 million and adjusted EBITDA guidance to $2–$7 million. Operational highlights include record specialty pharmacy fills driving a 58% year-over-year revenue increase in that segment, the addition of approximately 230,000 capitated lives through an exclusivity agreement in California, and new delegated contracts in Nevada and Oregon. Starling Oncology operates as a value-based community oncology group providing specialized cancer care.

The Oncology Institute, Inc. entered into a $75 million term loan agreement with Orbimed Opportunities (CA) V LLC, which was drawn in full on July 1, 2026. The company used the proceeds to fully repay $86 million in 4% senior secured convertible notes due 2027. Additionally, the company issued 10,025,535 warrants to Deerfield Partners, L.P. to purchase common stock at an exercise price of $8.567 per share. The Oncology Institute, Inc. operates in the healthcare sector, providing oncology-related medical services.